Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nadolol/Bendroflumethiazide · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg |
| 2 | ACTIVE_COMPARATOR | Corzide® Tablets 80 mg/5 mg |
| Name | Type | Description |
|---|---|---|
| Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg | DRUG | 80/5mg, single dose fed |
| Corzide® Tablets 80 mg/5 mg | DRUG | 80/5mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older 2. Sex: Male and/or non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (β-HCG) pregnancy tests performed within 21 days prior to the start of the study and on the evening...
Nadolol/Bendroflumethiazide is a fixed-dose combination small molecule product containing the beta-adrenergic antagonist nadolol and the thiazide diuretic bendroflumethiazide. It is being developed by Viatris Inc. (ticker VTRS) as Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and is currently in Phase 1 clinical development.
Nadolol/Bendroflumethiazide targets the beta-1 and beta-2 adrenergic receptors, known as ADRB1 and ADRB2. The nadolol component acts as an antagonist at these receptors, while bendroflumethiazide is a thiazide-type diuretic. This dual mechanism combines beta-blockade with diuretic activity in a single tablet formulation.
Nadolol/Bendroflumethiazide is being developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the sponsor of the clinical studies evaluating this fixed-dose combination product.
Nadolol/Bendroflumethiazide is in Phase 1 clinical development. Both of its recorded trials are Phase 1 studies that have been completed, and no trials are currently active. The program has enrolled a total of 108 participants across its studies to date.
Nadolol/Bendroflumethiazide has been evaluated in two completed Phase 1 trials: NCT00648297, a fed study with 42 participants, and NCT00647660, a fasting study with 66 participants. Both compared Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg with Corzide Tablets 80 mg/5 mg in healthy volunteers in the United States.